ATE555078T1 - Verfahren und zwischenprodukte - Google Patents

Verfahren und zwischenprodukte

Info

Publication number
ATE555078T1
ATE555078T1 AT01975197T AT01975197T ATE555078T1 AT E555078 T1 ATE555078 T1 AT E555078T1 AT 01975197 T AT01975197 T AT 01975197T AT 01975197 T AT01975197 T AT 01975197T AT E555078 T1 ATE555078 T1 AT E555078T1
Authority
AT
Austria
Prior art keywords
intermediate products
products
Prior art date
Application number
AT01975197T
Other languages
English (en)
Inventor
Ann Eldridge
Johann Hiebl
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Application granted granted Critical
Publication of ATE555078T1 publication Critical patent/ATE555078T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/22—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/22—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides
    • C07C319/24—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides by reactions involving the formation of sulfur-to-sulfur bonds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
AT01975197T 2000-09-12 2001-09-12 Verfahren und zwischenprodukte ATE555078T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23178400P 2000-09-12 2000-09-12
PCT/US2001/028443 WO2002022554A1 (en) 2000-09-12 2001-09-12 Process and intermediates

Publications (1)

Publication Number Publication Date
ATE555078T1 true ATE555078T1 (de) 2012-05-15

Family

ID=22870636

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01975197T ATE555078T1 (de) 2000-09-12 2001-09-12 Verfahren und zwischenprodukte

Country Status (11)

Country Link
US (2) US6570024B2 (de)
EP (1) EP1322597B1 (de)
JP (1) JP4886961B2 (de)
AR (1) AR030612A1 (de)
AT (1) ATE555078T1 (de)
AU (1) AU2001294549A1 (de)
CY (1) CY1112871T1 (de)
DK (1) DK1322597T3 (de)
ES (1) ES2383792T3 (de)
PT (1) PT1322597E (de)
WO (1) WO2002022554A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
AU2002311919B8 (en) 2001-05-11 2007-03-22 Ludwig Institute For Cancer Research Ltd Specific binding proteins and uses thereof
US7276497B2 (en) * 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
US8603483B2 (en) * 2004-12-09 2013-12-10 Janssen Biotech, Inc. Anti-integrin immunoconjugates, methods and uses
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
CA2680854C (en) 2007-03-15 2017-02-14 Ludwig Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
CN108424454B (zh) 2007-08-14 2022-05-31 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
MX2011012665A (es) 2009-06-04 2012-03-07 Novartis Ag Metodos para identificacion de sitios para conjugacion de igg.
US9290577B2 (en) 2009-07-03 2016-03-22 Avipep Pty Limited Immuno-conjugates and methods for producing them
CN102770456B (zh) 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
JP2013514788A (ja) 2009-12-23 2013-05-02 アビペップ ピーティーワイ リミテッド イムノコンジュゲート及びその作製方法２
KR20130009760A (ko) 2010-02-10 2013-01-23 이뮤노젠 아이엔씨 Ｃｄ２０ 항체 및 이의 용도
CA2799540A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
KR101972446B1 (ko) 2011-05-27 2019-04-25 글락소 그룹 리미티드 Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）­결합 단백질
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
WO2014182970A1 (en) 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
JP2016538283A (ja) 2013-11-13 2016-12-08 ザイムワークス，インコーポレイテッド Ｅｇｆｒ及び／またはｈｅｒ２を標的にする一価抗原結合性構築物及びその使用
SG11201701128YA (en) 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
US11420981B2 (en) * 2019-04-18 2022-08-23 Indena S.P.A. Diasteroselective process for the preparation of thiol- or disulfide-containing maytansinoid esters and intermediates thereof
CN117396513A (zh) 2021-05-28 2024-01-12 葛兰素史密斯克莱知识产权发展有限公司 治疗癌症的联合疗法
CA3233953A1 (en) 2021-10-05 2023-04-13 Matthew Bruce Combination therapies for treating cancer
WO2024218345A1 (en) 2023-04-21 2024-10-24 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE430062B (sv) * 1977-03-04 1983-10-17 Pharmacia Fine Chemicals Ab Kopplings- eller tioleringsreagens
JPS61112042A (ja) * 1985-07-31 1986-05-30 Wakunaga Seiyaku Kk 架橋試薬として適当な化合物
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
JP3408158B2 (ja) * 1998-07-17 2003-05-19 大日本製薬株式会社 スルトプリド誘導体及び抗スルトプリド抗体
US6573074B2 (en) * 2000-04-12 2003-06-03 Smithkline Beecham Plc Methods for ansamitocin production
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents

Also Published As

Publication number Publication date
JP4886961B2 (ja) 2012-02-29
EP1322597A4 (de) 2005-10-19
WO2002022554A1 (en) 2002-03-21
US6884874B2 (en) 2005-04-26
EP1322597B1 (de) 2012-04-25
ES2383792T3 (es) 2012-06-26
AR030612A1 (es) 2003-08-27
DK1322597T3 (da) 2012-07-02
AU2001294549A1 (en) 2002-03-26
JP2004509094A (ja) 2004-03-25
PT1322597E (pt) 2012-06-01
US6570024B2 (en) 2003-05-27
US20020156318A1 (en) 2002-10-24
EP1322597A1 (de) 2003-07-02
CY1112871T1 (el) 2016-04-13
US20040014980A1 (en) 2004-01-22

Similar Documents

Publication Publication Date Title
ATE555078T1 (de) Verfahren und zwischenprodukte
ATE283273T1 (de) Hemisynthetisches verfahren und dessen zwischenprudukte
ATE452540T1 (de) Zusammensetzung und verfahren
DE60139930D1 (de) Desinfizieruns- und desodorierungsverfahren
CY2008006I1 (el) Παραγωγα τροπανιου χρησιμα στη θepαπευτικη
DE60129522D1 (de) Gipszusammensetzungen und dazugehörende verfahren
FI19992360L (fi) Tuote ja menetelmä sen valmistamiseksi
DE60115902D1 (de) Osteoimplantat und verfahren zu seiner herstellung
DE60134496D1 (de) Polyesterverfahren
DE60138648D1 (de) Modulare atemgeräte und verfahren zum umbau derselben
DE60112988D1 (de) Kabelbaum und Herstellungsverfahren
DE59913180D1 (de) Produktebestellungsverfahren und system
DE60100770D1 (de) Doppelbahniger Förderbandreinigungsapparat und Verfahren
ATA10852001A (de) Bauelement und verfahren zu seiner herstellung
DE60132139D1 (de) Lautsprecher und Verfahren zum Zusammenbauen des Lautsprechers
DE50103327D1 (de) Mikromechanisches bauelement und entsprechendes herstellungsverfahren
DE60134540D1 (de) Töchiometrie aufweisender isolierschicht und verfahren zur herstellung
ATE286658T1 (de) Teigformmaschine und verfahren
DE60017012D1 (de) Orginalitätsverschluss und Herstellungverfahren
DE60116486D1 (de) Gallengangstent und verfahren zu seiner herstellung
DE69904731D1 (de) Feinzerkleinerer und feinzerkleinerungsverfahren
ATE322174T1 (de) Gefrorene süsswaren und herstellungsverfahren
DE60106372D1 (de) Redox System und Verfahren
EP1347866A4 (de) Holzprodukte und verfahren zur herstellung derselben
EP1299337A4 (de) Hydroxyphenstatin und seine promedikamente